Journal ArticleDOI
Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
TLDR
Evidence suggests that the GLP-1 RAs that predominantly target thePrandial glucose excursions, such as exenatide twice daily and lixisenatide once-daily prandial, are therefore best used as combination therapy with basal insulin and will form an important new treatment option for individuals with T2DM.About:
This article is published in Diabetes & Metabolism.The article was published on 2013-12-01. It has received 70 citations till now. The article focuses on the topics: Lixisenatide & Exenatide.read more
Citations
More filters
Journal ArticleDOI
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
TL;DR: The pharmacokinetics, pharmacodynamics and safety profiles, including cardiovascular safety, of currently available therapies for management of hyperglycaemia in patients with T2DM are assessed within the context of disease pathogenesis and natural history.
Journal ArticleDOI
Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
Juris J. Meier,Julio Rosenstock,Agnès Hincelin-Méry,Christine Roy-Duval,Astrid Delfolie,Hans-Veit Coester,Bjoern A. Menge,Thomas Forst,Christoph Kapitza +8 more
TL;DR: Lixisenatide and liraglutide improved glycemic control in optimized insulin glargine-treated T2D albeit with contrasting mechanisms of action and differing safety profiles.
Journal ArticleDOI
Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.
TL;DR: The already large reassuring experience with DPP-4 inhibitors in patients with CKD offers new opportunities to the clinician, whereas more caution is required with GLP-1 receptor agonists because of the limited experience in this population.
Journal ArticleDOI
Glycemic Variability: How to Measure and Its Clinical Implication for Type 2 Diabetes
TL;DR: Glycated hemoglobin A1c levels have traditionally been the gold standard for assessing glycemic control and treatment efficacy in patients with type 2 diabetes, however, A1C does not take into account fluctuations in blood glucose levels known as glycemic variability (GV).
Journal ArticleDOI
Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
TL;DR: SAR441255, a synthetic peptide agonist of the GLP-1, GCG, and GIP receptors, structurally based on the exendin-4 sequence, displays high potency with balanced activation of all three target receptors as discussed by the authors .
References
More filters
Journal ArticleDOI
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Silvio E. Inzucchi,Richard M. Bergenstal,John B. Buse,Michaela Diamant,Ele Ferrannini,Michael A. Nauck,Anne L. Peters,Apostolos Tsapas,Richard C. Wender,David R. Matthews,David R. Matthews,David R. Matthews +11 more
TL;DR: Properties of currently available glucose-lowering agents that may guide treatment choice in individual patients with type 2 diabetes mellitus are explored.
Journal ArticleDOI
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
TL;DR: Clinical trials with the incretin mimetic exenatide and liraglutide show reductions in fasting and postprandial glucose concentrations, and haemoglobin A1c (HbA1c) associated with weight loss, but long-term clinical studies are needed to determine the benefits of targeting the inc retin axis for the treatment of type 2 diabetes.
Journal ArticleDOI
Biology of Incretins: GLP-1 and GIP
TL;DR: This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).
Journal ArticleDOI
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Silvio E. Inzucchi,Richard M. Bergenstal,John B. Buse,Michaela Diamant,Ele Ferrannini,Michael A. Nauck,Anne L. Peters,Apostolos Tsapas,Richard C. Wender,David R. Matthews,David R. Matthews,David R. Matthews +11 more
TL;DR: This statement has been written incorporating the best available evidence and, where solid support does not exist, using the experience and insight of the writing group, incorporating an extensive review by additional experts (acknowledged below).
Journal ArticleDOI
Erratum: Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (Diabetologia (2013) 56 (680))
Silvio E. Inzucchi,Richard M. Bergenstal,John B. Buse,Michaela Diamant,Eleuterio Ferrannini,Matthias Nauck,Anne L. Peters,Apostolos Tsapas,Richard C. Wender,David R. Matthews,David R. Matthews,David R. Matthews +11 more
TL;DR: In this paper, the authors discuss the properties of currently available glucose-lowering agents that may guide treatment choice in individual patients with type 2 diabetes mellitus, including vildagliptin.